Revitalizing Healthcare.

Roivant Sciences is a global healthcare company focused on realizing the full value of promising biomedical research to improve the lives of patients and their families.

Who We Are

Roivant’s mission is to systematically reduce the time and cost of the drug development process. We partner with innovative biopharmaceutical companies and academic institutions to ensure that important medicines are rapidly delivered to patients. Our goal is to serve our partners, contribute positively to the healthcare system, and improve the lives of patients around the world.

Roivant is the parent of a growing family of companies focused on diverse therapeutic areas including neurology, dermatology, urology, endocrinology, women’s health, and rare diseases.
Learn More About Us

 

THE ROIVANT FAMILY OF COMPANIES

Axovant

Finding new solutions
for dementia.

THE ROIVANT FAMILY OF COMPANIES

Myovant

Dedicated to women’s
health and prostate cancer.

THE ROIVANT FAMILY OF COMPANIES

Enzyvant

Developing transformative therapies
for patients with rare diseases.

THE ROIVANT FAMILY OF COMPANIES

Dermavant

Leading innovation in
medical dermatology.

THE ROIVANT FAMILY OF COMPANIES

Urovant

Improving quality of life
through innovations in urology.

OUR WORK

Pipeline

We have a diverse pipeline of 14 investigational drugs in 6 therapeutic areas being tested in 39 clinical trials across our family of companies.

THERAPEUTIC AREA
COMPOUND
INDICATION
PHASE
therapeutic area Compound Indication PRECLIN Phase 1 Phase 2 Phase 3
NEUROLOGY INTEPIRDINE

Mild-to-Moderate Alzheimer's Disease

3

Dementia with Lewy Bodies (DLB)

2

Gait and Balance Impairments in Dementia

2

NELOTANSERIN

Visual Hallucinations in Lewy Body Dementia

2

REM Behavior Disorder (RBD) in DLB

2

RVT-103 and RVT-104

Alzheimer's Disease

1

ONCOLOGY RELUGOLIX

Prostate Cancer

3

ENDOCRINOLOGY RELUGOLIX

Uterine Fibroids

3

Endometriosis

3

MVT-602

Female Infertility

Preclin

RARE DISEASES RVT-801

Farber Disease

Preclin

RVT-802

Complete DiGeorge Syndrome

3

DERMATOLOGY RVT-501

Mild-to-Moderate Atopic Dermatitis

2

RVT-502

Moderate-to-Severe Dermatologic Indications

Preclin

RVT-201

Inflammatory Skin Diseases

1

UROLOGY VIBEGRON

Overactive Bladder

3

OTHER RVT-701

Autism

2

RVT-702

Undisclosed

Preclin

OUR PEOPLE

Leadership

Our leadership team includes industry veterans as well as exceptional leaders from outside of pharma.

The management teams of our subsidiary companies feature some of the most accomplished executives in the biopharmaceutical industry.

Our directors have deep experience in pharmaceutical business development, academic research, public policy, and life sciences investing.

Our Public Stakeholder Advisory Group (PSAG) provides continuing advice on how Roivant can play a role in improving the healthcare system.

WHO WE WORK WITH

Partners

We work with partners who share our patient-centric commitment to developing new medicines, helping them realize value from potential therapies beyond their core areas of focus. We seek investigational drugs with the potential to have a transformative impact on the lives of patients.

STAY INFORMED

News

GET IN TOUCH

Contact Us

Basel, Switzerland
Roivant Sciences GmbH
Viaduktstrasse 8
4051 Basel
Switzerland
New York, NY
Roivant Sciences, Inc.
320 West 37th Street
5th Floor
New York, NY 10018
United States
Durham, NC
Roivant Sciences, Inc.
324 Blackwell Street
Bay 12, Suite 1220
Durham, NC 27701
United States
San Francisco, CA
Myovant Sciences, Inc.
2000 Sierra Point Parkway
5th Floor
Brisbane, CA 94005
United States
Cambridge, MA
Enzyvant Sciences, Inc.
90 Broadway
Suite 204
Cambridge, MA 02142
United States